These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
246 related items for PubMed ID: 19609950
1. Increased expression of the heterogeneous nuclear ribonucleoprotein K in pancreatic cancer and its association with the mutant p53. Zhou R, Shanas R, Nelson MA, Bhattacharyya A, Shi J. Int J Cancer; 2010 Jan 15; 126(2):395-404. PubMed ID: 19609950 [Abstract] [Full Text] [Related]
2. Higher expression of the heterogeneous nuclear ribonucleoprotein k in melanoma. Wen F, Shen A, Shanas R, Bhattacharyya A, Lian F, Hostetter G, Shi J. Ann Surg Oncol; 2010 Oct 15; 17(10):2619-27. PubMed ID: 20499280 [Abstract] [Full Text] [Related]
3. Radiosensitization and downregulation of heterogeneous nuclear ribonucleoprotein K (hnRNP K) upon inhibition of mitogen/extracellular signal-regulated kinase (MEK) in malignant melanoma cells. Eder S, Lamkowski A, Priller M, Port M, Steinestel K. Oncotarget; 2015 Jul 10; 6(19):17178-91. PubMed ID: 26136337 [Abstract] [Full Text] [Related]
4. Expression levels of hnRNP K and p21WAF1/CIP1 are associated with resistance to radiochemotherapy independent of p53 pathway activation in rectal adenocarcinoma. Daskalaki W, Wardelmann E, Port M, Stock K, Steinestel J, Huss S, Sperveslage J, Steinestel K, Eder S. Int J Mol Med; 2018 Dec 10; 42(6):3269-3277. PubMed ID: 30272263 [Abstract] [Full Text] [Related]
5. hnRNP K: an HDM2 target and transcriptional coactivator of p53 in response to DNA damage. Moumen A, Masterson P, O'Connor MJ, Jackson SP. Cell; 2005 Dec 16; 123(6):1065-78. PubMed ID: 16360036 [Abstract] [Full Text] [Related]
7. Role of heterogeneous nuclear ribonucleoprotein K in tumor development. Chen Y, Zeng Y, Xiao Z, Chen S, Li Y, Zou J, Zeng X. J Cell Biochem; 2019 Sep 16; 120(9):14296-14305. PubMed ID: 31127648 [Abstract] [Full Text] [Related]
8. Regulation of the p53 expression profile by hnRNP K under stress conditions. Swiatkowska A, Dutkiewicz M, Machtel P, Janecki DM, Kabacinska M, Żydowicz-Machtel P, Ciesiołka J. RNA Biol; 2020 Oct 16; 17(10):1402-1415. PubMed ID: 32449427 [Abstract] [Full Text] [Related]
9. hnRNP K suppresses apoptosis independent of p53 status by maintaining high levels of endogenous caspase inhibitors. Xiao Z, Ko HL, Goh EH, Wang B, Ren EC. Carcinogenesis; 2013 Jul 16; 34(7):1458-67. PubMed ID: 23455382 [Abstract] [Full Text] [Related]
10. Cytoplasmic Accumulation of Heterogeneous Nuclear Ribonucleoprotein K Strongly Promotes Tumor Invasion in Renal Cell Carcinoma Cells. Otoshi T, Tanaka T, Morimoto K, Nakatani T. PLoS One; 2015 Jul 16; 10(12):e0145769. PubMed ID: 26713736 [Abstract] [Full Text] [Related]
11. Heterogeneous nuclear ribonucleoprotein K is a novel regulator of androgen receptor translation. Mukhopadhyay NK, Kim J, Cinar B, Ramachandran A, Hager MH, Di Vizio D, Adam RM, Rubin MA, Raychaudhuri P, De Benedetti A, Freeman MR. Cancer Res; 2009 Mar 15; 69(6):2210-8. PubMed ID: 19258514 [Abstract] [Full Text] [Related]
12. Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma development. Shilo A, Ben Hur V, Denichenko P, Stein I, Pikarsky E, Rauch J, Kolch W, Zender L, Karni R. RNA; 2014 Apr 15; 20(4):505-15. PubMed ID: 24572810 [Abstract] [Full Text] [Related]
13. Hdm2 is regulated by K-Ras and mediates p53-independent functions in pancreatic cancer cells. Sui X, Shin S, Zhang R, Firozi PF, Yang L, Abbruzzese JL, Reddy SA. Oncogene; 2009 Feb 05; 28(5):709-20. PubMed ID: 19029954 [Abstract] [Full Text] [Related]
14. Aberrant hnRNP K expression: All roads lead to cancer. Gallardo M, Hornbaker MJ, Zhang X, Hu P, Bueso-Ramos C, Post SM. Cell Cycle; 2016 Jun 17; 15(12):1552-7. PubMed ID: 27049467 [Abstract] [Full Text] [Related]
15. Expression, phosphorylation, and mRNA-binding of heterogeneous nuclear ribonucleoprotein K in Xenopus oocytes, eggs, and early embryos. Iwasaki T, Koretomo Y, Fukuda T, Paronetto MP, Sette C, Fukami Y, Sato K. Dev Growth Differ; 2008 Jan 17; 50(1):23-40. PubMed ID: 18042150 [Abstract] [Full Text] [Related]
16. SUMOylation of hnRNP-K is required for p53-mediated cell-cycle arrest in response to DNA damage. Lee SW, Lee MH, Park JH, Kang SH, Yoo HM, Ka SH, Oh YM, Jeon YJ, Chung CH. EMBO J; 2012 Nov 28; 31(23):4441-52. PubMed ID: 23092970 [Abstract] [Full Text] [Related]
17. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells. Barceló C, Etchin J, Mansour MR, Sanda T, Ginesta MM, Sanchez-Arévalo Lobo VJ, Real FX, Capellà G, Estanyol JM, Jaumot M, Look AT, Agell N. Gastroenterology; 2014 Oct 28; 147(4):882-892.e8. PubMed ID: 24998203 [Abstract] [Full Text] [Related]
18. MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Enge M, Bao W, Hedström E, Jackson SP, Moumen A, Selivanova G. Cancer Cell; 2009 Mar 03; 15(3):171-83. PubMed ID: 19249676 [Abstract] [Full Text] [Related]
19. Heterogeneous nuclear ribonucleoprotein K promotes the progression of lung cancer by inhibiting the p53-dependent signaling pathway. Li M, Yang X, Zhang G, Wang L, Zhu Z, Zhang W, Huang H, Gao R. Thorac Cancer; 2022 May 03; 13(9):1311-1321. PubMed ID: 35352475 [Abstract] [Full Text] [Related]
20. Dihydrosanguinarine suppresses pancreatic cancer cells via regulation of mut-p53/WT-p53 and the Ras/Raf/Mek/Erk pathway. Wu SZ, Xu HC, Wu XL, Liu P, Shi YC, Pang P, Deng L, Zhou GX, Chen XY. Phytomedicine; 2019 Jun 03; 59():152895. PubMed ID: 30913453 [Abstract] [Full Text] [Related] Page: [Next] [New Search]